Effects of sitagliptin, acarbose and sulfonylureas on postprandial levels of GLP-1 and GIP in Japanese patients with type 2 diabetes

被引：0
|
作者：
Yabe, D. [1 ]
Watanabe, K. [1 ]
Sugawara, K. [1 ]
Kuwata, H. [1 ]
Kitamoto, Y. [1 ]
Sugizaki, K. [1 ]
Fujiwara, S. [1 ]
Hishizawa, M. [1 ]
Hyo, T. [1 ]
Kuwabara, K. [1 ]
Yokota, K. [1 ]
Iwasaki, M. [1 ]
Kitatani, N. [1 ]
Kurose, T. [1 ]
Seino, Y. [1 ]
机构：
[1] Kansai Elect Power Hosp, Div Diabet Clin Nutr & Endocrinol, Osaka, Japan
来源：
DIABETOLOGIA | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
838
引用
收藏
页码：S342 / S342
页数：1
相关论文
共 50 条
  • [21] On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus
    Vilsboll, T
    DANISH MEDICAL BULLETIN, 2004, 51 (04) : 364 - 370
  • [22] GIP and GLP-1 receptor agonism in the therapy of type 2 diabetes with a focus on tirzepatide
    Nauck, Michael A.
    Blueher, Matthias
    Meyhoefer, Sebastian M.
    Heitmann, Elke
    Goergens, Sven W.
    DIABETOLOGIE UND STOFFWECHSEL, 2023, 18 (06) : 475 - 487
  • [23] The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
    Frias, Juan Pablo
    Bastyr, Edward J., III
    Vignati, Louis
    Tschoep, Matthias H.
    Schmitt, Christophe
    Owen, Klara
    Christensen, Rune Haubo
    DiMarchi, Richard D.
    CELL METABOLISM, 2017, 26 (02) : 343 - +
  • [24] Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
    Hartman, Mark L.
    Sanyal, Arun J.
    Loomba, Rohit
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Bray, Ross
    Karanikas, Chrisanthi A.
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    DIABETES CARE, 2020, 43 (06) : 1352 - 1355
  • [25] Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
    Tremblay, A. J.
    Lamarche, B.
    Deacon, C. F.
    Weisnagel, S. J.
    Couture, P.
    DIABETES OBESITY & METABOLISM, 2011, 13 (04): : 366 - 373
  • [26] Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects
    Gasbjerg, Laerke S.
    Helsted, Mads M.
    Sparre-Ulrich, Alexander H.
    Lanng, Amalie R.
    Stensen, Signe
    Jakobsen, Mette Hoy
    Hartmann, Bolette
    Christensen, Mikkel B.
    Holst, Jens J.
    Vilsboll, Tina
    Rosenkilde, Mette M.
    Knop, Filip K.
    DIABETES, 2018, 67
  • [27] Postprandial effects of individual and combined GIP and GLP-1 receptor antagonism in healthy subjects
    Gasbjerg, L. S.
    Helsted, M. M.
    Sparre-Ulrich, A. H.
    Lanng, A. R.
    Stensen, S.
    Jakobsen, M. H.
    Hartmann, B.
    Christensen, M. B.
    Holst, J. J.
    Vilsboll, T.
    Rosenkilde, M. M.
    Knop, F. K.
    DIABETOLOGIA, 2018, 61 : S246 - S246
  • [28] Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes
    Vale, Catarina
    Lourenco, Ines Mariana
    Jordan, Gabriela
    Golovaty, Ilya
    Torres, Hugo
    Moin, Tannaz
    Buysschaert, Martin
    Neves, Joao Sergio
    Bergman, Michael
    DIABETES OBESITY & METABOLISM, 2024,
  • [29] Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
    Pirro, Valentina
    Roth, Kenneth D.
    Lin, Yanzhu
    Willency, Jill A.
    Milligan, Paul L.
    Wilson, Jonathan M.
    Ruotolo, Giacomo
    Haupt, Axel
    Newgard, Christopher B.
    Duffin, Kevin L.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (02): : 363 - 378
  • [30] GLP-1 for type 2 diabetes
    Ahren, Bo
    EXPERIMENTAL CELL RESEARCH, 2011, 317 (09) : 1239 - 1245
12345